2/24
09:41 am
ogn
Organon & Co. (NYSE:OGN) had its price target raised by analysts at Barclays PLC from $7.50 to $8.00. They now have an "underweight" rating on the stock.
Low
Report
Organon & Co. (NYSE:OGN) had its price target raised by analysts at Barclays PLC from $7.50 to $8.00. They now have an "underweight" rating on the stock.
2/23
04:55 pm
ogn
Organon & Co. (OGN) Posts FY Adjusted EPS of $3.66, EBITDA Margin at 30.7% [Yahoo! Finance]
Medium
Report
Organon & Co. (OGN) Posts FY Adjusted EPS of $3.66, EBITDA Margin at 30.7% [Yahoo! Finance]
2/23
07:30 am
ogn
Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device
Low
Report
Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device
2/13
10:30 pm
ogn
Organon & Co. Q4 2025 Earnings Call Summary [Yahoo! Finance]
Low
Report
Organon & Co. Q4 2025 Earnings Call Summary [Yahoo! Finance]
2/13
01:38 am
ogn
Organon & Co. Q4 Earnings Call Highlights [Yahoo! Finance]
Medium
Report
Organon & Co. Q4 Earnings Call Highlights [Yahoo! Finance]
2/12
08:05 am
ogn
Organon in charts: Q4 revenue from Women's Health and Established Brands down; Biosimilars up Y/Y [Seeking Alpha]
Neutral
Report
Organon in charts: Q4 revenue from Women's Health and Established Brands down; Biosimilars up Y/Y [Seeking Alpha]
2/12
07:58 am
ogn
Earnings Snapshot: Organon & Co. misses bottom-line estimates; initiates FY26 outlook [Seeking Alpha]
Medium
Report
Earnings Snapshot: Organon & Co. misses bottom-line estimates; initiates FY26 outlook [Seeking Alpha]
2/12
07:30 am
ogn
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2025
Low
Report
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2025
1/31
07:46 am
ogn
Organon & Co. (NYSE:OGN) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
Medium
Report
Organon & Co. (NYSE:OGN) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
1/31
01:33 am
ogn
1/29
07:30 am
ogn
Organon To Report Fourth Quarter and Full Year 2025 Results and Host Conference Call on February 12, 2026
Medium
Report
Organon To Report Fourth Quarter and Full Year 2025 Results and Host Conference Call on February 12, 2026
1/28
12:45 pm
ogn
Organon Completes Divestiture of JADA® System to Laborie
Low
Report
Organon Completes Divestiture of JADA® System to Laborie
1/16
09:12 pm
ogn
Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON® (etonogestrel implant) 68 mg Radiopaque
Medium
Report
Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON® (etonogestrel implant) 68 mg Radiopaque
1/15
07:52 pm
ogn
Organon (OGN) Exceeds Market Returns: Some Facts to Consider [Yahoo! Finance]
Low
Report
Organon (OGN) Exceeds Market Returns: Some Facts to Consider [Yahoo! Finance]
1/8
01:30 am
ogn
Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo® in France, Denmark, Iceland, Sweden, Finland and Norway
Low
Report
Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo® in France, Denmark, Iceland, Sweden, Finland and Norway
1/3
01:08 am
ogn
Low
Report
12/10
07:18 am
ogn
Organon & Co. (NYSE:OGN) was upgraded by analysts at Barclays PLC to a "strong sell" rating.
Medium
Report
Organon & Co. (NYSE:OGN) was upgraded by analysts at Barclays PLC to a "strong sell" rating.
12/9
09:06 am
ogn
Organon & Co. (NYSE:OGN) is now covered by analysts at Barclays PLC. They set an "underweight" rating and a $7.50 price target on the stock.
Medium
Report
Organon & Co. (NYSE:OGN) is now covered by analysts at Barclays PLC. They set an "underweight" rating and a $7.50 price target on the stock.
12/1
10:24 am
ogn
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know [Yahoo! Finance]
Low
Report
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know [Yahoo! Finance]